West Pharmaceutical Services WST EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from West Pharmaceutical Services’s reported figures.
Based on trailing twelve months.
The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about West Pharmaceutical Services's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is West Pharmaceutical Services's EBITDA margin?
- West Pharmaceutical Services (WST) reported EBITDA margin of 25.8% in Q1 2026.
- How has West Pharmaceutical Services's EBITDA margin changed year-over-year?
- West Pharmaceutical Services's EBITDA margin increased by 4.8% year-over-year, from 24.6% to 25.8%.
- What is the long-term trend for West Pharmaceutical Services's EBITDA margin?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's EBITDA margin has grown at a -3.5% compound annual growth rate (CAGR), from 114.6% to 99.2%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.